DrugPatentWatch Database Preview
INVELTYS Drug Profile
Which patents cover Inveltys, and when can generic versions of Inveltys launch?
Inveltys is a drug marketed by Kala Pharms Inc and is included in one NDA. There are six patents protecting this drug.
This drug has forty-six patent family members in twelve countries.
The generic ingredient in INVELTYS is loteprednol etabonate. There are ten drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.
Summary for INVELTYS
| International Patents: | 46 |
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 45 |
| Patent Applications: | 2,275 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for INVELTYS |
| DailyMed Link: | INVELTYS at DailyMed |
Pharmacology for INVELTYS
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Synonyms for INVELTYS
| 034L466 |
| 82034-46-6 |
| AB00698349_08 |
| AB00698349-05 |
| AB00698349-07 |
| AB2000207 |
| AC1L9FKJ |
| AKOS005145741 |
| Alrex |
| Alrex;Lotemax |
| Androsta-1,4-diene-17-carboxylic acid, 17-((ethoxycarbonyl)oxy)-11-hydroxy-3-oxo-, chloromethyl ester, (11beta,17alpha)- |
| BCP28645 |
| C24H31ClO7 |
| CAS-82034-46-6 |
| CCG-101041 |
| CDDD 5604 |
| CDDD-5604 |
| CHEBI:31784 |
| CHEMBL1200865 |
| chloromethyl (1S,2R,10S,11S,14R,15S,17S)-14-[(ethoxycarbonyl)oxy]-17-hydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-14-carboxylate |
| chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-((ethoxycarbonyl)oxy)-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-17-carb |
| chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate |
| Chloromethyl 11beta,17-dihydroxy-3-oxoandrosta-1,4-diene-17beta-carboxylate, 17-(ethyl carbonate) |
| chloromethyl 17alpha-[(ethoxycarbonyl)oxy]-11beta-hydroxy-3-oxoandrosta-1,4-diene-17beta-carboxylate |
| CS-0900 |
| D01689 |
| DMKSVUSAATWOCU-HROMYWEYSA-N |
| DSSTox_CID_26468 |
| DSSTox_GSID_46468 |
| DSSTox_RID_81641 |
| DTXSID2046468 |
| GS-3599 |
| GTPL7085 |
| HGP 1 |
| HGP-1 |
| HMS2051F16 |
| HMS2232J09 |
| HMS3715N06 |
| HY-17358 |
| IDR-90102 |
| IDR-90103 |
| K462 |
| Locort |
| Loteflam |
| Lotemax |
| Lotemax (TN) |
| Loteprednol etabonate |
| Loteprednol etabonate (JAN/USAN) |
| Loteprednol etabonate [USAN:JAN] |
| Loteprednol etabonate Opphthalmic suspension |
| Loteprednol Etabonate, >=98% (HPLC) |
| Loteprednol-etabonate |
| Loterox |
| MLS001424221 |
| NC00291 |
| NCGC00164594-01 |
| NCGC00164594-02 |
| P 5604 |
| P-5604 |
| s1669 |
| SCHEMBL23907 |
| SMR000469178 |
| ST24030829 |
| Tox21_112219 |
| Tox21_112219_1 |
| UNII-YEH1EZ96K6 |
| YEH1EZ96K6 |
| ZINC3920673 |
US Patents and Regulatory Information for INVELTYS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kala Pharms Inc | INVELTYS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210565-001 | Aug 22, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Kala Pharms Inc | INVELTYS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210565-001 | Aug 22, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Kala Pharms Inc | INVELTYS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210565-001 | Aug 22, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for INVELTYS
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2016535777 | Start Trial |
| European Patent Office | 2844223 | Start Trial |
| Australia | 2013256092 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
